With standout facilities and strong industry links, the School prepares students for careers in health and medical science.
Doctorate in Science University Lausanne Switzerland
Master in Science Federal School Zurich (ETHZ)
Excludes commercial-in-confidence projects.
Development of an anti-cancer mitotic inhibitor MKI-77, Cancer Council SA - Beat Cancer, 01/07/2012 - 31/08/2013
Open access indicates that an output is open access.
de Wild, M, Muller, T, Tschumi, S, Schumacher, R & Albrecht, H 2012, 'Production and in-vitro characterization of micro-structured implant surfaces', in PJ Bartolo et al. (eds), Innovative developments in virtual and physical prototyping, CRC Press, UK, pp. 111-114.
Kübler, E & Albrecht, H 2018, 'Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines', Oncotarget, vol. 9, no. 38, pp. 24882-24897.
Zhang, W, Song, Y, Eldi, P, Guo, X, Hayball, JD, Garg, S & Albrecht, H 2018, 'Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles', International journal of nanomedicine, vol. 13, pp. 293-305.
Open access 1 1
Diab, S, Abdelaziz, AM, Li, P, Teo, T, Basnet, SK, Noll, B, Rahaman, MH, Lu, J, Hou, J, Yu, M, Le, BT, Albrecht, H, Milne, RW & Wang, S 2017, 'Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia', European journal of medicinal chemistry, vol. 24, no. 6, pp. 575-591.
Kumarasiri, M, Teo, T, Yu, M, Philip, S, Basnet, SK, Albrecht, H, Sykes, MJ, Wang, P & Wang, S 2017, 'In search of novel CDK8 inhibitors by virtual screening', Journal of chemical information and modeling, vol. 57, no. 3, pp. 413-416.
3 3 2
Lenjisa, JL, Tadesse, S, Khair, NZ, Kumarasiri, M, Yu, M, Albrecht, H, Milne, R & Wang, S 2017, 'CDK5 in oncology: recent advances and future prospects.', Future medicinal chemistry, vol. 9, no. 16, pp. 1939-1962.
Zeleke, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of medicinal chemistry, vol. 60, no. 5, pp. 1892-1915.
Open access 8 6
Li, P, Diab, S, Yu, M, Adams, J, Islam, S, MC Basnet, S, Albrecht, H, Milne, RW & Wang, S 2016, 'Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells', Oncotarget, vol.7, no.35, pp.1-15.
Open access 7 4
Rahaman, MH, Kumarasiri, M, Mekonnen, LB, Yu, M, Diab, S, Albrecht, H, Milne, RW & Wang, S 2016, 'Targeting CDK9: a promising therapeutic opportunity in prostate cancer', Endocrine-related cancer, vol. 23, no. 12, pp. T211-T226.
Open access 9 8 2
Zhang, W, Garg, S, Eldi, P, Zhou, FH-h, Johnson, IR, Brooks, DA, Lam, F, Rychkov, G, Hayball, JD & Albrecht, H 2016, 'Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide', International journal of pharmaceutics, vol. 513, pp.270-279.
9 7 1
MC Basnet, S, Diab, S, Schmid, R, Yu, M, Yang, Y, Gillam, TA, Teo, T, Li, P, Peat, T, Albrecht, H & Wang, S 2015, 'Identification of a highly conserved allosteric binding site on Mnk1 and Mnk2', Molecular Pharmacology, vol. 88, no. 5, pp. 935-948.
Open access 10 10
Teo, T, Yang, Y, Yu, M, MC Basnet, S, Gillam, T, Hou, J, Schmid, R, Kumarasiri, M, Diab, S, Albrecht, H, Sykes, M & Wang, S 2015, 'An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis', European Journal of Medicinal Chemistry, vol. 103, pp. 539-550.
15 13 5
Yu, M, Li, P, MC Basnet, S, Kumarasiri, M, Diab, S, Teo, T, Albrecht, H & Wang, S 2015, 'Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d[pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation', European journal of medicinal chemistry, vol. 95, pp. 116-126.
14 14 3
Diab, S, Teo, THS, Kumarasiri, M, Li, P, Yu, M, Lam, F, MC Basnet, S, Sykes, MJ, Albrecht, H, Milne, R & Wang, S 2014, 'Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors : synthesis, SAR analysis and biological evaluation', ChemMedChem, vol. 9, no. 5, pp. 962-972.
Open access 31 30 1
Joesch, C, Guevarra, E, Parel, S, Bergner, A, Zbinden, P, Konrad, D & Albrecht, H 2008, 'Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and µARCS technologies: Identification of ion channel modulators acting on the GABAA receptor', Journal of Biomolecular Screening, vol. 13, no. 3, pp. 218-228.
21 21 3
External engagement & recognition
|CSIRO Australia (Commonwealth Scientific Industrial Research Organisation)||AUSTRALIA|
|South Australian Health and Medical Research Institute (SAHMRI)||AUSTRALIA|
|University of Applied Sciences and Arts Northwestern Switzerland||SWITZERLAND|
|University of Applied Sciences Northwestern Switzerland||SWITZERLAND|
|University of South Australia||AUSTRALIA|
|Yabao Pharmaceutical Group Co., Ltd||CHINA|
Supervisions from 2010 shown
|Thesis title||Student status|
|CDKI-73 functions as CDK9 inhibitor in treatment of colorectal cancer||Current|
|Development of a colorectal stent delivery system for anticancer drugs||Current|
|Evaluation of anti-cancer efficacy of CDK inhibitors.||Current|
|Pharmacodynamics or pharmacokinetics of new anticancer drugs||Current|
|Pre-clinical development of a CDK inhibitor for cancer treatment||Current|
|Pre-clinical evaluation of FLT3 inhibitors for treatment of Acute Myeloid Leukaemia (AML)||Current|
|Targeting Cyclin-dependent kinases 4/6 for treatment of cancer||Current|
|Identification and characterisation of Mnk inhibitors as potential anti-cancer agents||Completed|
|Targeting prostate cancer cells with elastin like peptide based micelles displaying gastrin releasing peptide||Completed|